Skip to content
HEAL-SL

Adult Malaria Reduction Intervention Trial (AMRI)

An individually randomised, double-blind, placebo-controlled phase 2 trial of the R21/Pfs230 malaria vaccine in adults, recruiting through HEAL-SL sampling units. A pre-implementation pilot with dummy vaccination ran in Bo District in February 2026.

OngoingFrom 17 Feb 2026Bo
Bar chart of adults at each step of the AMRI pre-implementation pilot: 213 approached, 211 consented, 203 first dummy vaccination, 200 randomised, 185 second and 171 third dummy vaccination

Key findings

  • Pre-implementation pilot: of 213 adults approached, 211 (99%) consented; 203 were eligible and received the first dummy vaccination.
  • Pre-implementation pilot: 200 of the 203 were randomised electronically; 3 could not be assigned because their vial barcodes were not recognised.
  • Pre-implementation pilot: of 200 randomised, 185 (92.5%) received the second dummy vaccination and 171 (85.5%) the third.
  • Pre-implementation pilot: venous blood was collected from 103 participants, against a target of 100.

About this study

Background

Round one of HEAL-SL identified malaria as the leading cause of death in children and adults. The Adult Malaria Reduction Intervention Trial (AMRI) tests the combined R21/Pfs230 malaria vaccine in adults. It is registered as PACTR202501701465667 and recruits from the HEAL-SL sampling frame.

Design

The trial has three arms: vaccine at months 0, 1 and 2; vaccine at months 0 and 1 with placebo at month 2; and placebo. A safety cohort of 300 adults comes first. After review by a Data and Safety Monitoring Board, 6,000 more adults are to be enrolled in Bo and Pujehun districts. The Sierra Leone Ethics and Scientific Review Committee approved the trial on 17 December 2025 (SLESRC No. 016/12/2025).

What was done

A pre-implementation pilot, one of the trial's activities, ran in Bo District from 17 to 28 February 2026, in three areas and 103 households. It used a dummy vaccination to test recruitment, consent, randomisation, vaccination, safety observation, specimen collection, data capture and retention.

Results

Of 213 adults approached, 211 (99%) consented, and 203 were eligible and received the first dummy vaccination. Of 200 randomised, 185 (92.5%) received the second dummy vaccination and 171 (85.5%) the third.

Status

As of September 2026 the definitive trial had not started. A manuscript on the pilot was submitted to a journal on 19 October 2026.

Outputs

  • Assessing the Feasibility of a Decentralised Community-Based Model for Clinical Trial Delivery in a Resource-Limited Setting: Lessons from a Structured Pre-Implementation Pilot in Sierra Leone

    In reviewJournal article · October 2026

    Submitted to a journal on 19 October 2026.

Study team

Partners
  • Njala University
  • National Public Health Agency of Sierra Leone
  • National Malaria Control Programme
  • Centre for Global Health Research, University of Toronto
  • University of Oxford
  • London School of Hygiene & Tropical Medicine
  • Serum Institute of India (funder)
Study leads
  • Prof Rashid Ansumana — Njala University
  • Prof Foday Sahr — National Public Health Agency of Sierra Leone
  • Prof Prabhat Jha — University of Oxford
  • Dr Abdul Mac Falama — National Malaria Control Programme